Last update Oct. 12, 2022

Rhinopront™

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Rhinopront is a tradename that contains several active ingredients in its composition:

  • Carbinoxamine Maleate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Phenylpropanolamine; Phenylpropanolamine Hydrochloride (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)

Since each active ingredient of this product may have a different level of risk for breastfeeding, we establish that of the product with higher risk.

For more information (pharmacokinetics, references, ...) tap each active ingredient.

Note: The composition of certain tradenames varies in each country. Please, make sure this is the composition of the tradename you are looking for..

Alternatives

Carbinoxamine Maleate

Phenylpropanolamine; Phenylpropanolamine Hydrochloride

  • Cetirizine Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Desloratadine (Safe substance and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe substance and/or breastfeeding is the best option.)
  • Liraglutide (Safe substance and/or breastfeeding is the best option.)
  • Maternal Sport (Safe substance and/or breastfeeding is the best option.)
  • Orlistat (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Pseudoephedrine (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Total visits

3,482

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM